Marginal Corneal Infiltration Following Treatment for Metastatic Breast Cancer with Triple Chemotherapy of Trastuzumab, Pertuzumab & Docetaxel

References

• Nagy P, Jenei A, Damjanovich S, et al. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res. 1999;5:255–271. doi:10.1053/paor.1999.0255.
   PubMedGoogle Scholar
• Jerjian TV, Glode AE, Thompson LA, O’Bryant CL. Antibody–drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy. Pharmacotherapy. 2016;36:99–116. doi:10.1002/phar.1687.
   PubMed Web of Science ®Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330–9336. doi:10.1158/0008-5472.CAN-08-4597.
   PubMed Web of Science ®Google Scholar
• Morse DL. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 2005;4:1495–1504. doi:10.1158/1535-7163.MCT-05-0130.
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Shu S, Yorozu K, et al. Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model. Oncol Lett. 2017;14(4):4197–4205. doi:10.3892/ol.2017.6679.
   PubMed Web of Science ®Google Scholar
• Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006;8:216. doi:10.1186/bcr1618.
   PubMed Web of Science ®Google Scholar
• Mannell A. The role of Ki-67 in breast cancer. S Afr J Surg. 2016;54:10‐13.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang J, Ding M, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2017;20(5):570–575. doi:10.1007/s12094-017-1774-3.
   PubMed Web of Science ®Google Scholar
• Sánchez-Muñoz A, Navarro-Perez V, Plata-Fernández Y, et al. Proliferation determined by Ki-67 defines different pathologic response to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. Clin Breast Cancer. 2015;15(5):343‐347.
   PubMed Web of Science ®Google Scholar
• Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea. 2000 Sep;19(5):625–643. doi:10.1097/00003226-200009000-00008.
   PubMed Web of Science ®Google Scholar
• Szabó DJ, Noer A, Nagymihály R, et al. Long-term cultures of human cornea limbal explants form 3D structures ex vivo - implications for tissue engineering and clinical applications. PLoS One. 2015;10(11):e0143053. doi:10.1371/journal.pone.0143053.
   PubMed Web of Science ®Google Scholar
• Jumblatt MM, McKenzie RW, Steele PS, Emberts CG, Jumblatt JE. MUC7 expression in the human lacrimal gland and conjunctiva. Cornea. 2003;22(1):41–45. doi:10.1097/00003226-200301000-00010.
   PubMed Web of Science ®Google Scholar
• Conrady CD, Joos ZP, Patel BC. Review: the lacrimal gland and its role in dry eye. J Ophthalmol. 2016;2016:7542929. doi:10.1155/2016/7542929.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012 Jan;130(1):90–100. doi:10.1001/archophthalmol.2011.364.
   PubMedGoogle Scholar
• Robboy MW, Comstock TL, Kalsow CM. Contact lens–associated corneal infiltrates. Eye Contact Lens. 2003;29(3):146–154. doi:10.1097/01.ICL.0000072830.41886.1E.
   PubMedGoogle Scholar
• Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res. 2004;23:449–474. doi:10.1016/j.preteyeres.2004.04.003.
   PubMed Web of Science ®Google Scholar
• Xu KP, Riggs A, Ding Y, Yu FS. Role of ErbB2 in corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2004;45:4277–4283. doi:10.1167/iovs.04-0119.
   PubMedGoogle Scholar
• Orlandi A, Fasciani R, Cassano A, et al. Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report. BMC Cancer. 2015;15(1):973. doi:10.1186/s12885-015-1969-3.
   PubMedGoogle Scholar
• Arango ME, Li P, Komatsu M, Montes C, Carraway CA, Carraway KL. Production and localization of Muc4/sialomucin complex and its receptor tyrosine kinase ErbB2 in the rat lacrimal gland. Invest Ophthalmol Vis Sci. 2001;42:2749–2756.
   PubMed Web of Science ®Google Scholar
• You S, Kublin CL, Avidan O, Miyasaki D, Zoukhri D. Isolation and propagation of mesenchymal stem cells from the Lacrimal Gland. Invest Ophthalmol Vis Sci. 2011;52(5):2087–2094. doi:10.1167/iovs.10-5686.
   PubMed Web of Science ®Google Scholar
• Joseph A, Powell-Richards AO, Shanmuganathan VA, Dua HS. Epithelial cell characteristics of cultured human limbal explants. Br J Ophthalmol. 2004;88(3):393‐398. doi:10.1136/bjo.2003.018481.
   Web of Science ®Google Scholar
• Trastuzumab summary of product characteristics. https://www.medicines.org.Uk/emc/product/3856/smpc. Accessed October 01, 2020.
   Google Scholar
• Chalvatzis N, Manthou ME, Tzamalis A, Hytiroglou P, Dimitrakos S. Erosive conjunctival and corneal inflammatory changes in a patient receiving weekly docetaxel for breast cancer. Ocul Immunol Inflamm. 2014;22(2):164–166. doi:10.3109/09273948.2013.812221.
   PubMed Web of Science ®Google Scholar
• Robin JB, Schanzlin DJ, Verity SM, et al. Peripheral corneal disorders. Surv Ophthalmol. 1986 Jul-Aug;31(1):1–36. doi:10.1016/0039-6257(86)90049-4.
   PubMed Web of Science ®Google Scholar
• Yagci A. Update on peripheral ulcerative keratitis. Clin Ophthalmol. 2012;6:747–754. doi:10.2147/OPTH.S24947.
   PubMedGoogle Scholar
• Del Castillo JM, de la Casa JM, Sardiña RC, et al. Treatment of recurrent corneal erosions using autologous serum. Cornea. 2002;21(8):781–783. doi:10.1097/00003226-200211000-00010.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984–1989. doi:10.1016/S0161-6420(99)90412-8.
   PubMed Web of Science ®Google Scholar
• Partal A, Scott E. Low-cost protocol for the production of autologous serum eye drops by blood collection and processing centres for the treatment of ocular surface diseases. Transfus Med. 2011;21(4):271–277. doi:10.1111/j.1365-3148.2011.01072.x.
   PubMed Web of Science ®Google Scholar
• Lekhanont K, Jongkhajornpong P, Choubtum L, et al. Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery. Biomed Res Int. 2013;2013:1–7.
   PubMed Web of Science ®Google Scholar
• Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. British J Ophthalmol. 2004;88(11):1467–1474. doi:10.1136/bjo.2004.044347.
   PubMed Web of Science ®Google Scholar
• Rauz S, Koay SY, Foot B, et al. The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report. Eye (Lond). 2017 Nov 17. doi:10.1038/eye.2017.209.
   Web of Science ®Google Scholar
• Cho YK, Huang W, Kim GY, et al. Comparison of autologous serum eye drops with different diluents. Curr Eye Res. 2013;38(1). doi:10.3109/02713683.2012.720340.
   Web of Science ®Google Scholar